180 related articles for article (PubMed ID: 37170284)
1. EnGraft: a multicentre, open-label, randomised, two-arm, superiority study protocol to assess bioavailability and practicability of Envarsus® versus Advagraf™ in liver transplant recipients.
Wöhl DS; James B; Götz M; Brennfleck F; Holub-Hayles I; Mutzbauer I; Baccar S; Brunner SM; Geissler EK; Schlitt HJ;
Trials; 2023 May; 24(1):325. PubMed ID: 37170284
[TBL] [Abstract][Full Text] [Related]
2. A multi-center interventional study to assess pharmacokinetics, effectiveness, and tolerability of prolonged-release tacrolimus after pediatric kidney transplantation: study protocol for a prospective, open-label, randomized, two-phase, two-sequence, single dose, crossover, phase III b trial.
Karaterzi S; Tönshoff B; Ahlenstiel-Grunow T; Baghai M; Beck B; Büscher A; Eifler L; Giese T; Lezius S; Müller C; Oh J; Zapf A; Weber LT; Pape L
Front Nephrol; 2024; 4():1331510. PubMed ID: 38444519
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
Staatz CE; Tett SE
Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.
Kamar N; Cassuto E; Piotti G; Govoni M; Ciurlia G; Geraci S; Poli G; Nicolini G; Mariat C; Essig M; Malvezzi P; Le Meur Y; Garrigue V; Del Bello A; Rostaing L
Adv Ther; 2019 Feb; 36(2):462-477. PubMed ID: 30552587
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Controlled Trial of Envarsus Versus Immediate Release Tacrolimus in Kidney Transplant Recipients With Delayed Graft Function.
Parajuli S; Muth B; Bloom M; Ptak L; Aufhauser D; Thiessen C; Al-Adra D; Mezrich J; Neidlinger N; Odorico J; Wang JG; Foley D; Kaufman D; Mandelbrot DA
Transplant Proc; 2023 Sep; 55(7):1568-1574. PubMed ID: 37394382
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients.
Garnock-Jones KP
Drugs; 2015 Feb; 75(3):309-20. PubMed ID: 25613762
[TBL] [Abstract][Full Text] [Related]
8. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients.
Lu Z; Bonate P; Keirns J
Br J Clin Pharmacol; 2019 Aug; 85(8):1692-1703. PubMed ID: 30950096
[TBL] [Abstract][Full Text] [Related]
10. Envarsus, a novelty for transplant nephrologists: Observational retrospective study.
Franco A; Más-Serrano P; Balibrea N; Rodriguez D; Javaloyes A; Díaz M; Gascón I; Ramon-Lopez A; Perez-Contreras J; Selva J; Nalda-Molina R
Nefrologia (Engl Ed); 2019; 39(5):506-512. PubMed ID: 30850218
[TBL] [Abstract][Full Text] [Related]
11. Once- versus twice-daily tacrolimus: are the formulations truly equivalent?
Barraclough KA; Isbel NM; Johnson DW; Campbell SB; Staatz CE
Drugs; 2011 Aug; 71(12):1561-77. PubMed ID: 21861541
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations.
Henin E; Govoni M; Cella M; Laveille C; Piotti G
Adv Ther; 2021 Oct; 38(10):5317-5332. PubMed ID: 34515977
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
[TBL] [Abstract][Full Text] [Related]
14. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability.
Muduma G; Odeyemi I; Pollock RF
J Med Econ; 2014 Jul; 17(7):520-6. PubMed ID: 24754700
[TBL] [Abstract][Full Text] [Related]
15. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
[TBL] [Abstract][Full Text] [Related]
16. Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in
Budde K; Rostaing L; Maggiore U; Piotti G; Surace D; Geraci S; Procaccianti C; Nicolini G; Witzke O; Kamar N; Albano L; Büchler M; Pascual J; Gutiérrez-Dalmau A; Kuypers D; Wekerle T; Głyda M; Carmellini M; Tisone G; Midtvedt K; Wennberg L; Grinyó JM
Transpl Int; 2022; 35():10225. PubMed ID: 36017158
[No Abstract] [Full Text] [Related]
17. Advagraf® with or without an induction therapy for de novo kidney-transplant recipients.
Noble J; Jouve T; Rostaing L; Malvezzi P
Expert Rev Clin Immunol; 2018 Jun; 14(6):461-467. PubMed ID: 29757021
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.
Fernandez Rivera C; Calvo Rodríguez M; Poveda JL; Pascual J; Crespo M; Gomez G; Cabello Pelegrin S; Paul J; Lauzurica R; Perez Mir M; Moreso F; Perelló M; Andres A; González E; Fernandez A; Mendiluce A; Fernández Carbajo B; Sanchez Fructuoso A; Calvo N; Suarez A; Bernal Blanco G; Osuna A; Ruiz-Fuentes MC; Melilli E; Montero Perez N; Ramos A; Fernández B; López V; Hernandez D;
Clin Transplant; 2022 Mar; 36(3):e14550. PubMed ID: 34851532
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial.
Fischer L; Trunečka P; Gridelli B; Roy A; Vitale A; Valdivieso A; Varo E; Seehofer D; Lynch S; Samuel D; Ericzon BG; Boudjema K; Karpf C; Undre N
Liver Transpl; 2011 Feb; 17(2):167-77. PubMed ID: 21280190
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study.
Lehner LJ; Reinke P; Hörstrup JH; Rath T; Suwelack B; Krämer BK; Budde K; Banas B
Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29052906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
